5 Best Low-Priced Growth Stocks To Buy

2. Fate Therapeutics, Inc. (NASDAQ:FATE)

Number of Hedge Fund Holders: 25

Yet another biotech stock on our list, California-based Fate Therapeutics, Inc. (NASDAQ:FATE) makes cellular immunotherapies for cancer and immune disorders. In February, Fate Therapeutics, Inc. (NASDAQ:FATE) posted its Q4 results which were better than expectations. GAAP EPS in the quarter came in at -$0.58, beating estimates by $0.29. Revenue in the quarter increased by 160% year over year to total $44.34 million, beating estimates by $25.93 million.

As of the end of the fourth quarter of 2022, 25 hedge funds tracked by Insider Monkey had stakes in Fate Therapeutics, Inc. (NASDAQ:FATE). The biggest stakeholder of Fate Therapeutics, Inc. (NASDAQ:FATE) was Jeremy Green’s Redmile Group which had a $131 million stake.